ReviewNeuro-oncology2016
Biology and management of ependymomas.
Review in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03727841 (Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma), which is not on this map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Clinical Trial of Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 185 citations in OpenAlex.
- EANS-EANO guidelines on the extent of resection in gliomas.Neuro-oncology · 2026Guideline
- Extra-Neural Metastases From Primary Intracranial Ependymomas: A Systematic Review.Frontiers in oncology · 2022Pooled it
- Spinal ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes with a focus on the pediatric population (Part III of ependymomas across compartments).Journal of neuro-oncology · 2026Review
- Intracranial ependymoma and secondary hydrocephalus: a rare case report in a Camel (Frontiers in veterinary science · 2026Article
- Case Report: A case of diffuse midline glioma, H3 K27-altered presenting with long-segment spinal cord lesions.Frontiers in oncology · 2026Article
- Intracranial ependymoma grade II with lipomatous metaplasia: a case report and literature review.Frontiers in oncology · 2026Article
- Building a dynamic web calculator for individualized conditional survival estimation in brainstem ependymoma.Scientific reports · 2025Article
- Recurrent parietal lobe supratentorial ependymoma, ZFTA fusion-positive, CNS WHO grade 3, with new dural and calvarial reactive changes in a child: illustrative case.Journal of neurosurgery. Case lessons · 2025Article
- Review
- Liquid Biopsy for Spinal Tumors: On the Frontiers of Clinical Application.Global spine journal · 2025Article
- Intracranial ependymoma: A retrospective analysis of clinical features, treatment modalities, and long-term outcome.Aging medicine (Milton (N.S.W)) · 2024Article
- Clustering-independent estimation of cell abundances in bulk tissues using single-cell RNA-seq data.Cell reports methods · 2024Article
- Clustering-independent estimation of cell abundances in bulk tissues using single-cell RNA-seq data.bioRxiv : the preprint server for biology · 2024Article
- Conditional survival estimates for ependymomas reveal the dynamic nature of prognostication.Discover oncology · 2024Article
- Differentiating Low-Grade from High-Grade Intracranial Ependymomas: Comparison of Dynamic Contrast-Enhanced MRI and Diffusion-Weighted Imaging.AJNR. American journal of neuroradiology · 2024Article
- Adolescents and Young Adults With Cancer: CNS Tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
- New CNS tumor classification: The importance in pediatric neurosurgical practice.Surgical neurology international · 2024Review
- Machine learning-based nomogram for distinguishing between supratentorial extraventricular ependymoma and supratentorial glioblastoma.Frontiers in oncology · 2024Article
- "Soap bubble" sign as an imaging marker for posterior fossa ependymoma Group B.Neuroradiology · 2023Article
- Recurrent intracranial anaplastic ependymoma with late-onset giant scalp metastasis.Clinical case reports · 2023Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Ependymomas are rare primary tumors of the central nervous system in children and adults that comprise histologically similar but genetically distinct subgroups. The tumor biology is typically more associated with the site of origin rather than being age-specific. Genetically distinct subgroups have been identified by genomic studies based on locations in classic grade II and III ependymomas. They are supratentorial ependymomas with C11orf95-RELA fusion or YAP1 fusion, infratentorial ependymomas with or without a hypermethylated phenotype (CIMP), and spinal cord ependymomas. Myxopapillary ependymomas and subependymomas have different biology than ependymomas with typical WHO grade II or III histology. Surgery and radiotherapy are the mainstays of treatment, while the role of chemotherapy has not yet been established. An in-depth understanding of tumor biology, developing reliable animal models that accurately reflect tumor molecule features, and high throughput drug screening are essential for developing new therapies. Collaborative efforts between scientists, physicians, and advocacy groups will enhance the translation of laboratory findings into clinical trials. Improvements in disease control underscore the need to incorporate assessment and management of patients' symptoms to ensure that treatment advances translate into improvement in quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.